Day: ខែកុម្ភៈ 5, 2026
SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners
OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a ......
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the ......
Hitachi significantly expands exhibits at the “Hitachi Building Solutions Lab”, a research facility for collaborative creation with customers
- A branding area showcasing Hitachi’s journey from its founding to the vision it aims to achieve through Inspire 2027.(Top left)- A three-sided immersive theater presenting the future of buildings through powerful, engaging visual experiences.(Top right)- The entrance to the exhibition area where visitors can experience Hitachi’s comprehensive capabilities broughttogether under the One Hitachi. (Bottom left)- An interactive corner that visualizes and demonstrates commercial air conditioning control using augmented realitytechnology. (Bottom right)TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. (“Hitachi Building Systems”, part of Hitachi’s Connective Industries Sector (“CI Sector”)) will significantly expand the exhibits at “Hitachi Building Solutions Lab”, a customer co-creation research facility. The facility, located in Tokyo, will reopen in its new form on ......